Your browser is no longer supported. Please, upgrade your browser.
OREX Orexigen Therapeutics, Inc. monthly Stock Chart
OREX [NASD]
Orexigen Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.78 Insider Own0.10% Shs Outstand14.72M Perf Week11.83%
Market Cap45.93M Forward P/E- EPS next Y-5.95 Insider Trans0.00% Shs Float14.72M Perf Month8.71%
Income-71.30M PEG- EPS next Q-2.40 Inst Own53.50% Short Float17.48% Perf Quarter-21.61%
Sales47.80M P/S0.96 EPS this Y67.90% Inst Trans14.31% Short Ratio14.26 Perf Half Y68.65%
Book/sh-0.53 P/B- EPS next Y39.60% ROA-22.90% Target Price4.00 Perf Year-37.34%
Cash/sh5.89 P/C0.53 EPS next 5Y- ROE-253.10% 52W Range1.65 - 5.70 Perf YTD79.31%
Dividend- P/FCF- EPS past 5Y22.00% ROI-17.40% 52W High-45.26% Beta2.48
Dividend %- Quick Ratio2.80 Sales past 5Y50.30% Gross Margin70.30% 52W Low89.09% ATR0.18
Employees132 Current Ratio3.20 Sales Q/Q282.00% Oper. Margin- RSI (14)55.94 Volatility6.82% 5.84%
OptionableYes Debt/Eq- EPS Q/Q-203.90% Profit Margin- Rel Volume1.11 Prev Close3.09
ShortableYes LT Debt/Eq- EarningsAug 08 AMC Payout- Avg Volume180.46K Price3.12
Recom3.00 SMA205.82% SMA502.40% SMA200-0.31% Volume201,022 Change0.97%
Mar-16-16Reiterated RBC Capital Mkts Sector Perform $1 → $0.60
Mar-16-16Downgrade Piper Jaffray Overweight → Neutral
Mar-16-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $5 → $1
Feb-29-16Downgrade JP Morgan Overweight → Neutral
Feb-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Dec-11-15Resumed BofA/Merrill Underperform
Dec-04-15Downgrade Wells Fargo Outperform → Market Perform
Nov-06-15Reiterated RBC Capital Mkts Outperform $9 → $5
Oct-06-15Reiterated Piper Jaffray Overweight $21 → $11
Mar-27-15Reiterated RBC Capital Mkts Outperform $10 → $14
Jan-23-15Initiated RBC Capital Mkts Outperform $10
Jan-10-14Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Outperform $10
Sep-21-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $5
Feb-01-11Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-01-11Downgrade Canaccord Genuity Buy → Hold
Dec-03-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform
Jul-16-10Reiterated JMP Securities Mkt Outperform $16 → $13
Jul-16-10Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Jun-16-17 08:15AM  Edison Issues Outlook on Orexigen Therapeutics (OREX) Accesswire
Jun-14-17 03:11AM  Orexigen (OREX) Down 9.4% Since Earnings Report: Can It Rebound? Zacks
Jun-05-17 02:38PM  ETFs with exposure to Orexigen Therapeutics, Inc. : June 5, 2017 Capital Cube
Jun-02-17 10:16AM  Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-24-17 10:38AM  5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio Zacks
May-19-17 08:04AM  The 3 Best Obesity-Drug Stocks to Buy in 2017 Motley Fool
May-17-17 10:07AM  Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth Zacks
May-16-17 04:10PM  Orexigen Announces Activities at European Congress on Obesity 2017 PR Newswire
May-10-17 08:05PM  Edited Transcript of OREX earnings conference call or presentation 9-May-17 9:00pm GMT Thomson Reuters StreetEvents
10:21AM  Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y Zacks
May-09-17 05:08PM  Orexigen reports 1Q loss Associated Press
04:01PM  Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 PR Newswire
01:00PM  Investor Network: Orexigen Therapeutics, Inc. to Host Earnings Call Accesswire
May-02-17 04:57PM  Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcare Conference PR Newswire
04:26PM  ETFs with exposure to Orexigen Therapeutics, Inc. : May 2, 2017 Capital Cube
03:01AM  Navamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of Mysimba® GlobeNewswire
03:00AM  Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic Countries PR Newswire
Apr-28-17 07:30AM  Today's Research Reports on Stocks to Watch: GrubHub and Orexigen Therapeutics Accesswire -6.65%
Apr-25-17 06:05PM  Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on May 9, 2017 PR Newswire
01:55AM  Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada PR Newswire
Apr-17-17 01:02PM  ETFs with exposure to Orexigen Therapeutics, Inc. : April 17, 2017 Capital Cube
Apr-05-17 05:14PM  ETFs with exposure to Orexigen Therapeutics, Inc. : April 5, 2017 Capital Cube
02:40PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Mar-31-17 09:57AM  Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017 Capital Cube -11.57%
Mar-30-17 04:07PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
09:30AM  Orexigen Releases Q4 Results, Vivus Reacquires Stendra from Sanofi Accesswire
06:07AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Mar-29-17 10:34AM  Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y Zacks -5.90%
10:34AM  Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y at Investopedia
Mar-28-17 09:46PM  Edited Transcript of OREX earnings conference call or presentation 28-Mar-17 9:00pm GMT Thomson Reuters StreetEvents
05:01PM  Orexigen reports 4Q loss Associated Press
05:00PM  Orexigen Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today
04:35PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:21PM  Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 PR Newswire
11:07AM  Orexigen Inks Commercialization Deal for Contrave, Stock Up Zacks
07:07AM  Q4 2016 Orexigen Therapeutics Inc Earnings Release - Before Market Open
Mar-27-17 06:03PM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Bruno Farmaceutici S.p.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy PR Newswire
Mar-20-17 07:25AM  How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma PR Newswire
Mar-08-17 06:10AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-07-17 08:56PM  Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017 PR Newswire
Feb-27-17 09:30AM  Biotech's Rise Shows No Sign of Slowing Down in 2017: Today's Reports on IntelliPharmaCeutics and Orexigen Therapeutics Accesswire
Feb-24-17 04:07PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina +11.56%
Feb-17-17 08:56AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and -6.41%
Feb-09-17 07:27AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +12.66%
Feb-07-17 04:40PM  Orexigen Therapeutics to Speak at Upcoming Investor Conferences PR Newswire +9.31%
Feb-06-17 05:23PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-25-17 07:40AM  Orexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmaceuticos Rovi, S.A. PR Newswire
Jan-12-17 06:08AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +5.94%
Jan-11-17 08:47AM  Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU -5.04%
Jan-10-17 09:13AM  Orexigen Therapeutics (OREX) Shares March Higher, Can It Continue?
08:55AM  Celgene Issues Preliminary 2016 Results, Lifts 2017 View
Jan-09-17 08:15AM  Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
06:11AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-06-17 08:05AM  Orexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl extended-release tablets) Real-World Study Results in "Obesity" PR Newswire -10.58%
Jan-05-17 07:50AM  Orexigen Therapeutics Highlights Key Business Priorities for 2017 PR Newswire +11.18%
Jan-04-17 12:15PM  Wednesdays Top 5 Biopharma Movers +64.25%
Jan-03-17 08:29PM  Orexigen Therapeutics Launches "Brains Behind Weight Loss," a Dynamic Patient Focused Campaign to Educate Consumers on the Role of the Brain in Weight Loss PR Newswire +18.97%
Dec-30-16 09:03AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events
Dec-23-16 01:56PM  15 Stocks With The Highest Forecast Sales Growth
Dec-21-16 12:43PM  ETFs with exposure to Orexigen Therapeutics, Inc. : December 21, 2016
Dec-20-16 06:08AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and +5.71%
Dec-19-16 08:10AM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl prolonged release) for Ten Countries in the Middle East PR Newswire -6.91%
07:40AM  Orexigen Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference 2017 PR Newswire
Dec-12-16 08:35AM  Should You Avoid Orexigen Therapeutics, Inc. (OREX)? at Insider Monkey -5.00%
Dec-09-16 12:32PM  ETFs with exposure to Orexigen Therapeutics, Inc. : December 9, 2016
Dec-08-16 07:25AM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Consilient Health Ltd. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in the UK and Ireland PR Newswire +5.43%
Nov-23-16 09:09AM  Edited Transcript of OREX earnings conference call or presentation 3-Nov-16 9:00pm GMT
Nov-16-16 04:15PM  Orexigen Announces Presentation of Data for OREX-1019, a Preclinical Candidate for the Treatment and Management of Drug Addiction PR Newswire
Nov-15-16 01:04PM  OREXIGEN THERAPEUTICS, INC. Financials
Nov-14-16 02:06PM  ETFs with exposure to Orexigen Therapeutics, Inc. : November 14, 2016
Nov-08-16 07:30AM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave® (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand PR Newswire -5.02%
Nov-07-16 11:43AM  Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016
06:06AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-04-16 04:41PM  Orexigen (OREX) Posts Narrower-than-Expected Loss in Q3
Nov-03-16 05:13PM  Orexigen beats 3Q profit forecasts -8.30%
05:00PM  Orexigen Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today
04:18PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:01PM  Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016 PR Newswire
07:07AM  Q3 2016 Orexigen Therapeutics Inc Earnings Release - After Market Close
Nov-02-16 04:30PM  Orexigen Therapeutics to Present at 25th Annual Credit Suisse Healthcare Conference PR Newswire
Oct-31-16 01:58PM  ETFs with exposure to Orexigen Therapeutics, Inc. : October 31, 2016 -7.27%
Oct-21-16 09:00AM  Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2016 Financial Results on November 3, 2016 PR Newswire
Oct-17-16 04:11PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits
Oct-04-16 10:13AM  ETFs with exposure to Orexigen Therapeutics, Inc. : October 4, 2016
Sep-16-16 11:18AM  ETFs with exposure to Orexigen Therapeutics, Inc. : September 16, 2016
Sep-07-16 04:10PM  Orexigen Therapeutics to Speak at the Rodman & Renshaw 18th Annual Global Investment Conference PR Newswire -5.08%
Aug-31-16 11:41AM  ETFs with exposure to Orexigen Therapeutics, Inc. : August 31, 2016
09:11AM  Orexigen Stock Up on Commercialization Deal for Contrave
Aug-30-16 08:00AM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release) PR Newswire
Aug-15-16 10:41AM  ETFs with exposure to Orexigen Therapeutics, Inc. : August 15, 2016
Aug-12-16 11:26AM  Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
Aug-05-16 02:23PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report +6.84%
Aug-04-16 06:05PM  Orexigen reports 2Q loss +6.69%
05:00PM  Orexigen Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today
04:09PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:01PM  Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016 PR Newswire
07:07AM  Q2 2016 Orexigen Therapeutics Inc Earnings Release - After Market Close
Aug-01-16 08:31AM  Orexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales Organization PR Newswire
08:30AM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Laboratorios Farmaceuticos Rovi, S.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain PR Newswire
06:13AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Regulation FD Dis
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moglia Stephen A.VP, Chief Accounting OfficerDec 19Sale1.968001,5680Dec 21 12:11 PM